• Dendritic spines depleted by Aβ42 and rescued by CLR01
  • Aβ42 fibrils and oligomers (inset) visualized by electron microscopy
  • Amyloid plaques and neurofibrillary tangles in a mouse brain before and after treatment with CLR01
  • Time-dependent change in the circular dichroism spectrum of Aβ during aggregation
  • Insulin microcrystals in the absence (A) or presence (B) of CLR01
  • Neurons (NeuN) and astrocytes (GFAP) in a tauopathy mouse brain
  • Aβ40 fibrils and oligomers (inset) visualized by electron microscopy
  • Islet amyloid polypeptide fibrils and oligomers (inset) visualized by electron microscopy

Gal Bitan, Ph.D.
Professor of Neurology
David Geffen School of Medicine at UCLA

Announcement: Dr. Suman Dutta is a Guest Editor of a new Research Topic, Exosomes: Message in a Vesicle that will be published in the section of Experimental Pharmacology and Drug Discovery by Frontiers in Pharmacology (IF: 4.225).  Drs. Gal Bitan, Kendall van Keuren-Jensen, and Satish Balasaheb Nimse are co-editors. Submission is now open! You are invited to submit your new and exciting original research on this topic to this new Research Topic. 

Announcement: Check out our lab's profile on the Department of Neurology's website.

 

Research

Our main research focus is the abnormal self-association of proteins into toxic oligomers, aggregates, and amyloid fibrils and the involvement of these aberrant protein assemblies in human diseases. We study the molecular interactions involved in these processes and explore novel tools to inhibit the formation of the toxic assemblies.

Abnormal protein oligomerization and aggregation cause, or are involved in, over 50 diseases called amyloidoses or proteinopathies. Of this large family of diseases, we study  Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and other more rare diseases. Another focus of our lab is the analysis of biomarkers that can improve the diagnosis and facilitate drug development for these diseases.

One of our major projects is the development of "Molecular Tweezers" as novel drug candidates for proteinopathies. We are leading a project called Breakthrough Treatment for Degenerative Diseases (www.BTDD.org) that involves collaboration with multiple laboratories at UCLA and around the world.